JP2020536903A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536903A5
JP2020536903A5 JP2020520290A JP2020520290A JP2020536903A5 JP 2020536903 A5 JP2020536903 A5 JP 2020536903A5 JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020536903 A5 JP2020536903 A5 JP 2020536903A5
Authority
JP
Japan
Prior art keywords
formulation
prostate cancer
castration
pharmaceutical composition
prednisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017438 external-priority patent/WO2019074536A1/en
Publication of JP2020536903A publication Critical patent/JP2020536903A/ja
Publication of JP2020536903A5 publication Critical patent/JP2020536903A5/ja
Pending legal-status Critical Current

Links

JP2020520290A 2017-10-11 2018-02-08 アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法 Pending JP2020536903A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
US62/570,781 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (2)

Publication Number Publication Date
JP2020536903A JP2020536903A (ja) 2020-12-17
JP2020536903A5 true JP2020536903A5 (cg-RX-API-DMAC7.html) 2021-03-11

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520290A Pending JP2020536903A (ja) 2017-10-11 2018-02-08 アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法

Country Status (16)

Country Link
US (2) US20190105332A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694604A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020536903A (cg-RX-API-DMAC7.html)
KR (1) KR20200068689A (cg-RX-API-DMAC7.html)
CN (1) CN111542373A (cg-RX-API-DMAC7.html)
AU (1) AU2018347804A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007090A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077678A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090916A1 (cg-RX-API-DMAC7.html)
IL (1) IL273826A (cg-RX-API-DMAC7.html)
JO (1) JOP20200072A1 (cg-RX-API-DMAC7.html)
MA (1) MA50341A (cg-RX-API-DMAC7.html)
MX (1) MX2020003830A (cg-RX-API-DMAC7.html)
PH (1) PH12020550151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124865C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019074536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Similar Documents

Publication Publication Date Title
Windle et al. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer
TWI729394B (zh) 雄性激素受體調節劑及其用途
Ramírez et al. New non-bisphosphonate drugs that produce osteonecrosis of the jaws
Van Dodewaard-De Jong et al. New treatment options for patients with metastatic prostate cancer: what is the optimal sequence?
Pincus et al. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis
Biancone et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study
JP2020503269A5 (cg-RX-API-DMAC7.html)
JP2020500864A5 (cg-RX-API-DMAC7.html)
de Miguel Novoa et al. Guidelines for diagnosis and treatment of adrenal insufficiency in adults
Vis et al. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?
JP2025159082A (ja) ホットフラッシュの新規処置法
Hyer et al. Early and late toxicity of radioiodine therapy: detection and management
Shetty et al. Lesion sterilization and tissue repair in primary teeth
Charalambous Seeking optimal management for radioactive iodine therapy-induced adverse effects
JP2020536055A5 (cg-RX-API-DMAC7.html)
Karunakar et al. Comparative evaluation of efficacy of diclofenac and ketoprofen administered using transdermal drug delivery route in management of post endodontic pain: A randomized controlled clinical trial
Fuller et al. Postoperative pain management with oral methylprednisolone in symptomatic patients with a pulpal diagnosis of necrosis: a prospective randomized, double-blind study
Ged et al. Management of castrate-resistant prostate cancer in older men
Sakai et al. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer
Haghighat et al. The effectiveness of GECB pastille in reducing complications of dry socket syndrome
Herlofson et al. Osteonecrosis of the jaw in a patient with bone metastatic prostate cancer after long-term bisphosphonate treatment with severe deterioration following radium-223
Santiago et al. Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.
Rizzoli Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis
Borrega et al. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer
Karavasilis et al. Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy